Home > Insider Trading > Filing (0001562180-24-000673)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1314102	Eyepoint Pharmaceuticals Inc.	EYPT	Laboratory Analytical Instruments (3826)	262774444

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1779458	Scott David Jones	C/O Eyepoint Pharmaceuticals, Inc. 480 Pleasant Street Watertown MA 02472	Svp & Chief Commercial Officer	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2024-01-24	5,600	$12.90	43,562	No	4	M	Direct
Common Stock	Acquisiton	2024-01-24	5,700	$3.26	49,262	No	4	M	Direct
Common Stock	Disposition	2024-01-24	5,700	$25.01	43,562	No	4	S	Direct
Common Stock	Disposition	2024-01-24	5,600	$25.01	37,962	No	4	S	Direct
Common Stock	Acquisiton	2024-01-25	300	$12.90	38,262	No	4	M	Direct
Common Stock	Acquisiton	2024-01-25	300	$3.26	38,562	No	4	M	Direct
Common Stock	Disposition	2024-01-25	300	$25.00	38,262	No	4	S	Direct
Common Stock	Disposition	2024-01-25	300	$25.00	37,962	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2024-01-24	5,600	$0.00	5,600	$12.90
Common Stock	Stock Option (Right to Buy)	Disposition	2024-01-24	5,700	$0.00	5,700	$3.26
Common Stock	Stock Option (Right to Buy)	Disposition	2024-01-25	300	$0.00	300	$12.90
Common Stock	Stock Option (Right to Buy)	Disposition	2024-01-25	300	$0.00	300	$3.26

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
18,625	2030-02-28	No	4	M	Direct
85,455	2033-01-05	No	4	M	Direct
18,325	2030-02-28	No	4	M	Direct
85,155	2033-01-05	No	4	M	Direct

Footnotes

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.00 to $25.09. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.00 to $25.25. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
The option to purchase vests and becomes exercisable ratably in forty-eight monthly installments which began March 28, 2020
The option to purchase vests and becomes exercisable as follows: 25% at January 6th, 2024 and the remainder ratably, on a monthly basis, over the remaining three years.